Radiation Oncology

CAR-T

Questions discussed in this category

How do you incorporate radiation therapy in patients undergoing CAR T-cell therapy for DLBCL?

2 Answers available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2019-12-01

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

The Lancet. Oncology, 2019-01

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Cancer immunology research, 2019-07

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Br J Haematol, 2020 Mar 5

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Lancet, 2020 Sep 01

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Blood Adv,

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Int J Radiat Oncol Biol Phys, 2020 May 22

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.

The New England journal of medicine, 2017-12-28

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Radiother Oncol, 2021 Dec 7

Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.

Related Topics in Radiation Oncology